Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 7, 2017

Primary Completion Date

June 16, 2020

Study Completion Date

June 16, 2020

Conditions

Migraine

Interventions

DRUG

TEV-48125

TEV-48125 will be administered subcutaneously once every 4 weeks.

DRUG

TEV-48125

TEV-48125 will be administered subcutaneously once every 12 weeks.

Trial Locations (1)

Saitama Medical University Hospital, Iruma